[go: up one dir, main page]

LU100797B1 - 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition - Google Patents

2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition Download PDF

Info

Publication number
LU100797B1
LU100797B1 LU100797A LU100797A LU100797B1 LU 100797 B1 LU100797 B1 LU 100797B1 LU 100797 A LU100797 A LU 100797A LU 100797 A LU100797 A LU 100797A LU 100797 B1 LU100797 B1 LU 100797B1
Authority
LU
Luxembourg
Prior art keywords
cyclodextrin
hydroxypropyl
treatment
beta
parkinsonian condition
Prior art date
Application number
LU100797A
Inventor
Javier Martin Jarazo
Jonas Walter
Jens Christian Schwamborn
Original Assignee
Univ Luxembourg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Luxembourg filed Critical Univ Luxembourg
Priority to LU100797A priority Critical patent/LU100797B1/en
Priority to PCT/EP2019/062469 priority patent/WO2019219741A1/en
Application granted granted Critical
Publication of LU100797B1 publication Critical patent/LU100797B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/724—Cyclodextrins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

The present invention relates to 2-hydroxypropyl-p-cyclodextrin for use in a method of treatment of a parkinsonian condition selected from the group consisting of: Parkinson's disease, Parkinsonism and Parkinson-plus syndrome as well as methods and uses based thereon. The present invention further relates to an isolated dopaminergic neuron or an isolated precursor cell thereof exposed to 2-hydroxypropyl-ß-cyclodextrin as well as methods and uses based thereon.
LU100797A 2018-05-15 2018-05-15 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition LU100797B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
LU100797A LU100797B1 (en) 2018-05-15 2018-05-15 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition
PCT/EP2019/062469 WO2019219741A1 (en) 2018-05-15 2019-05-15 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LU100797A LU100797B1 (en) 2018-05-15 2018-05-15 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition

Publications (1)

Publication Number Publication Date
LU100797B1 true LU100797B1 (en) 2019-11-15

Family

ID=62713048

Family Applications (1)

Application Number Title Priority Date Filing Date
LU100797A LU100797B1 (en) 2018-05-15 2018-05-15 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition

Country Status (2)

Country Link
LU (1) LU100797B1 (en)
WO (1) WO2019219741A1 (en)

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060945A2 (en) * 2003-12-24 2005-07-07 Archimedes Development Limited Intranasal compositions comprising zolpidem
WO2008038119A2 (en) * 2006-09-29 2008-04-03 Rosario Ammirante A composition comprising a coenzyme q10 - cyclodextrin - complex and a carotene and use thereof for the treatment of pathologic states of e.g. the central nervous system
EP2052719A1 (en) * 2007-10-23 2009-04-29 Nippon Hypox Laboratories Incorporated Curative drug for neurodegenerative diseases
WO2009109001A1 (en) 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function
EP2138173A1 (en) * 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
WO2011152869A1 (en) * 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2016168772A1 (en) * 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
US20170042932A1 (en) 2015-06-10 2017-02-16 Vtesse, Inc. Hydroxypropyl Beta-Cyclodextrin Compositions and Methods
WO2019067269A2 (en) * 2017-09-28 2019-04-04 Asdera Llc Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9815785D0 (en) * 1998-07-20 1998-09-16 Cerebrus Ltd Chemical compounds
US20200000840A1 (en) * 2016-03-20 2020-01-02 Asdera Llc Use of cyclodextrins to reduce endocytosis in malignant and neurodegenerative disorders

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005060945A2 (en) * 2003-12-24 2005-07-07 Archimedes Development Limited Intranasal compositions comprising zolpidem
WO2008038119A2 (en) * 2006-09-29 2008-04-03 Rosario Ammirante A composition comprising a coenzyme q10 - cyclodextrin - complex and a carotene and use thereof for the treatment of pathologic states of e.g. the central nervous system
EP2052719A1 (en) * 2007-10-23 2009-04-29 Nippon Hypox Laboratories Incorporated Curative drug for neurodegenerative diseases
WO2009109001A1 (en) 2008-03-04 2009-09-11 Adelaide Research & Innovation Pty Ltd Method for preventing and/or treating a disease, condition or state associated with reduced dopaminergic neuron function
EP2138173A1 (en) * 2008-06-26 2009-12-30 Merz Pharma GmbH & Co.KGaA Pharmaceutical compositions comprising aminoadamantane derivatives
WO2011152869A1 (en) * 2010-06-02 2011-12-08 Diffusion Pharmaceuticals Llc Oral formulations of bipolar trans carotenoids
WO2016168772A1 (en) * 2015-04-17 2016-10-20 Sens Research Foundation, Inc. Cyclodextrin compounds for the prevention and treatment of aging
US20170042932A1 (en) 2015-06-10 2017-02-16 Vtesse, Inc. Hydroxypropyl Beta-Cyclodextrin Compositions and Methods
US9675634B2 (en) 2015-06-10 2017-06-13 Vtesse Inc. Hydroxypropyl beta-cyclodextrin compositions and methods
WO2019067269A2 (en) * 2017-09-28 2019-04-04 Asdera Llc Use of cyclodextrins in diseases and disorders involving phospholipid dysregulation

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Remington's Pharmaceutical Sciences", 1980
"UniProtKB", Database accession no. Q96DA2
A. D. MCNAUGHTA. WILKINSON: "Gold Book", 1997, BLACKWELL SCIENTIFIC PUBLICATIONS, article "Compendium of Chemical Terminology"
BRAS, J.GUERREIRO, R.HARDY, J.: "SnapShot: Genetics of Parkinson's Disease", CELL, vol. 160, 2015, pages 570 - 5700
CAMARGO F ET AL: "CYCLODEXTRINS IN THE TREATMENT OF A MOUSE MODEL OF NIEMANN-PICK C DISEASE", LIFE SCIENCES, vol. 70, no. 2, 30 November 2001 (2001-11-30), pages 131 - 142, XP001086615, ISSN: 0024-3205, DOI: 10.1016/S0024-3205(01)01384-4 *
CARLOS ROSADODALIBOR MIJALJICAIRENE HATZINISIRIOUMARK PRESCOTTRODNEY J. DEVENISH: "A fluorescent pH-biosensor for reporting vacuolar turnover of cytosol and organelles in yeast", ROSELLA, 14 December 2007 (2007-12-14), pages 205 - 213
CAROLINE COISNE ET AL: "Cyclodextrins as Emerging Therapeutic Tools in the Treatment of Cholesterol-Associated Vascular and Neurodegenerative Diseases", MOLECULES, vol. 21, no. 12, 20 December 2016 (2016-12-20), pages 1748 - 1, XP055548026, DOI: 10.3390/molecules21121748 *
FAHN, S.: "The medical treatment of Parkinson disease from James Parkinson to George Cotzias", MOVEMENT DISORDERS, vol. 30, 2015, pages 4 - 18
FARRER, M.: "Genetics of Parkinson disease: paradigm shifts and future prospects", NATURE REVIEWS GENETICS, vol. 7, 2006
GOEDERT, M.SPILLANTINI, M.TREDICI, K.BRAAK, H.: "100 years of Lewy pathology", NATURE REVIEWS NEUROLOGY, vol. 9, 2012, pages 13 - 24
HOCKEMEYER, D.SOLDNER, F.BEARD, C.GAO, Q.MITALIPOVA, M.DEKELVER, R.C.KATIBAH, G.E.AMORA, R.BOYDSTON, E.A.ZEITLER, B.: "Efficient targeting of expressed and silent genes in human ESCs and iPSCs using zinc-finger nucleases", NATURE BIOTECHNOLOGY, vol. 27, 2009, pages 851, XP055390559, DOI: 10.1038/nbt.1562
KIRI KILPATRICK ET AL: "Genetic and Chemical Activation of TFEB Mediates Clearance of Aggregated [alpha]-Synuclein", PLOS ONE, vol. 10, no. 3, 19 March 2015 (2015-03-19), pages e0120819, XP055582176, DOI: 10.1371/journal.pone.0120819 *
KLEIN, C.WESTENBERGER, A.: "Genetics of Parkinson's Disease", vol. 2, 2012, COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
LANGER, SCIENCE, vol. 249, 1990, pages 1527 - 1533
LOZANO, C. S.TAM, J.LOZANO, A. M.: "The changing landscape of surgery for Parkinson's Disease", MOVEMENT DISORDERS, vol. 33, 2018, pages 36 - 47
LUN A ET AL: "Long-term effects of postnatal hypoxia and flunarizine on the dopaminergic system", PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, vol. 46, no. 4, December 1993 (1993-12-01), pages 867 - 871, XP025539159, ISSN: 0091-3057, [retrieved on 19931201], DOI: 10.1016/0091-3057(93)90215-F *
MALANGA MSZEMAN JFENYVESI EPUSKAS ICSABAI KGYEMANT GFENYVESI FSZENTE L: "Back to the Future'': A New Look at Hydroxypropyl Beta-Cyclodextrins", J PHARM SCI, vol. 105, no. 9, 14 June 2016 (2016-06-14), pages 2921 - 2931, XP055526940, DOI: 10.1016/j.xphs.2016.04.034
MONZEL, A.S.SMITS, L.M.HEMMER, K.HACHI, S.MORENO, E.VAN WUELLEN, T.JARAZO, J.WALTER, J.BRUGGEMANN, I.BOUSSAAD, I. ET AL.: "Derivation of Human Midbrain-Specific Organoids from Neuroepithelial Stem Cells", STEM CELL REPORTS, vol. 8, 2017, pages 1144 - 1154
PICKRELL, A. M.YOULE, R. J.: "The roles of PINK1, parkin, and mitochondrial fidelity in Parkinson's disease", NEURON, vol. 85, 2015, pages 257 - 273
POEWE, W. ET AL.: "Parkinson disease", NATURE REVIEWS DISEASE PRIMERS, 2017, pages 3
PRZEDBORSKI, S.: "The two-century journey of Parkinson disease research", NATURE REVIEWS NEUROSCIENCE, vol. 18, 2017
REINHARDT, P.GLATZA, M.HEMMER, K.TSYTSYURA, Y.THIEL, C.S.HOING, S.MORITZ, S.PARGA, J.A.WAGNER, L.BRUDER, J.M. ET AL.: "Derivation and Expansion Using Only Small Molecules of Human Neural Progenitors for Neurodegenerative Disease Modeling", PLOS ONE, 2013, pages 8
SARGSYAN, A.CAI, J.FANDINO, L.B.LABASKY, M.E.FOROSTYAN, T.COLOSIMO, L.K.THOMPSON, S.J.GRAHAM, T.E.: "Rapid parallel measurements of macroautophagy and mitophagy in mammalian cells using a single fluorescent biosensor", SCIENTIFIC REPORTS, vol. 5, 2015, pages 12397
SCHAPIRA, A. H. V.TOLOSA, E.: "Molecular and clinical prodrome of Parkinson disease: implications for treatment", NATURE REVIEWS NEUROLOGY, vol. 6, 2010, pages 309 - 317
YERGEY, A. L. ET AL.: "Characterization of hydroxypropyl-beta-cyclodextrins used in the treatment of Niemann-Pick Disease type C1", PLOS ONE, vol. 12, 2017
YU JVODYANIK MASMUGA-OTTO KANTOSIEWICZ-BOURGET JFRANE JLTIAN SNIE JJONSDOTTIR GARUOTTI VSTEWART R: "Induced pluripotent stem cell lines derived from human somatic cells", SCIENCE, vol. 318, no. 5858, 20 November 2007 (2007-11-20), pages 1917 - 20

Also Published As

Publication number Publication date
WO2019219741A1 (en) 2019-11-21

Similar Documents

Publication Publication Date Title
AU2018284960A1 (en) AADC polynucleotides for the treatment of Parkinson's disease
WO2016168784A3 (en) Rna nanoparticles and method of use thereof
SA521421115B1 (en) Carbidopa and L-DOPA Prodrugs and Methods of Use
MX2019015578A (en) Methods for treating huntington's disease.
MX2019015580A (en) Methods for treating huntington's disease.
WO2011130675A3 (en) Dopaminergic neurons differentiated from pluripotent stem cells and uses of thereof
EP2166991A4 (en) PVA-PAA HYDROGELS
MY205372A (en) Imp-producing microorganism and method of producing imp using the same
EP4295909A3 (en) Carbidopa and l-dopa prodrugs and methods of use
MX2019005165A (en) Hydrogen sulfide releasing polymer compounds.
MX340807B (en) Novel compositions for preventing and/or treating degenerative disorders of the central nervous system.
PH12020551007A1 (en) Anti-alpha-synuclein antibodies
MX2021006463A (en) Methods for the treatment of trinucleotide repeat expansion disorders associated with msh3 activity.
WO2019157527A3 (en) Methods related to parkinson's disease and synucleinopathies
MX2021006980A (en) Anti-il-27 antibodies and uses thereof.
MX2021006682A (en) Decarboxylase inhibitors for treating parkinson's disease.
MX2009009362A (en) Novel dosage form.
PH12015502687A1 (en) Marker for acid sphingomyelinase disorders and uses thereof
PH12017501304A1 (en) Levodopa and carbidopa intestinal gel and method of use
MX2019001946A (en) Marker for neural stem cells.
WO2008118792A3 (en) Gamma delta t cells and methods of treatment of interleukin-17 related conditions
LU100797B1 (en) 2-hydroxypropyl-beta-cyclodextrin for use in a method of treatment of a parkinsonian condition
WO2018158542A8 (en) Mesenchymal stem cells obtained from wharton's jelly for the treatment of sepsis
MX2021004085A (en) The use of a h3r inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (pd).
WO2018128722A8 (en) Use of gut microbiota in the diagnosis and therapeutics of parkinson's disease

Legal Events

Date Code Title Description
FG Patent granted

Effective date: 20191115